Coherus Looks To Raise $200m Amid Coronavirus Impact
Comes As Firm Warns Of Possible COVID-19 Adversity
Coherus BioSciences plans to dip into the financing market once again in order to fuel its operations, which include several biosimilar candidates in late-stage clinical development. However, at the same time, the firm has acknowledged the damage the accelerating COVID-19 crisis could have on operations, if only for a short while.
